Description du projet
L’intelligence artificielle au service du traitement du diabète
Le diabète est une maladie métabolique chronique qui entraîne de graves complications de santé et touche des millions de personnes et d’enfants dans le monde. Il nécessite un traitement à long terme par des spécialistes et une auto prise en charge quotidienne par le patient. Si l’utilisation d’applications de téléphonie mobile a permis d’améliorer la santé des diabétiques, il reste important d’identifier une application cliniquement pertinente parmi les milliers disponibles aujourd’hui sur le marché. Le projet DIABETESMART, financé par l’UE, propose une plateforme mobile pour la prise en charge quotidienne du diabète. Cette plateforme, validée cliniquement et classée IIA, est conforme au nouveau règlement européen sur les dispositifs médicaux. Elle est alimentée par l’intelligence artificielle et fournit des recommandations personnalisées en fonction du style de vie individuel et du contexte du pays. Cette innovation intègre le dispositif médical sanguin de l’utilisateur et le système portable de son choix, et permet ainsi aux patients de mener une vie normale.
Objectif
Diabetes mellitus, a common chronic disease that is associated with high blood glucose (also called blood sugar) can lead to potentially fatal health complications. Globally, 415 million people were diagnosed with diabetes in 2015, estimated to reach 642 million by 2040. In Europe disease prevalence is high, 66 million people were diagnosed in 2017, estimate to reach 81 million people by 2045, with 28,200 children (bellow 19 years old) diagnosed each year. Diabetes requires long-life care management from a physician care team and patient daily self-management. Improvement of diabetes self-care was shown when people with diabetes used mobile phone application. Yet, the challenge is to identify a clinical relevant App between the thousand diabetes management applications available in the market. Hedia, a Danish pioneer start-up company was founded with the mission to make life easier for people with diabetes. Based on the current challenges, we have developed a mobile platform for the daily diabetes management that outperforms the current stat-of-the-art: clinically validated Class IIA compliant to Europes’s new MDR; an artificial intelligent powered that provides tailored recommendations based on the individuals lifestyle and country context; integrate the user’s blood medical device and wearable of choice and other advanced features that enable people with diabetes live a normal life.
DIABETESMART project targets the diabetes care market, which has an estimate value of €69.10B in 2016, forecast to reach €137.28B by 2022 with a 12.4% CAGR (2016-2022). We aim to offer DIABETESMART to corporates -who will obtain further revenues of €18M per year- and to people with diabetes who will benefit from real-time clinically meaningful insights based on AI by 2021. We foresee to reach revenues of €26.6 million with €75.1 million in cumulative profits and increase our team to at least 25 employees (from current 11) by 2026.
Champ scientifique
- medical and health sciencesclinical medicineendocrinologydiabetes
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phones
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
2200 KOBENHAVN
Danemark
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.